Amprenavir安瑞那韦,161814-49-9

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Amprenavir

CAS No. : 161814-49-9

MCE 国际站：Amprenavir

产品活性：Amprenavir (VX-478) 是HIV蛋白酶抑制剂，Ki为0.6 nM。Amprenavir 也是 SARS-CoV 3CL^pro 的抑制剂，IC₅₀ 为 1.09 μM。

研究领域：Anti-infection  |  Metabolic Enzyme/Protease

作用靶点：HIV  |  HIV Protease  |  SARS-CoV

In Vitro: Amprenavir has an enzyme inhibition constant (Ki = 0.6 nM) that falls within the Ki range of the other protease inhibitors. Amprenavir's in vitro 50% inhibitory concentration (IC50) against wild-type clinical HIV isolates is 14.6 +/- 12.5 ng/mL (mean +/- SD) [1]. Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation [2].

In Vivo: Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic and overall anti-tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors [2]. Amprenavir efficiently activated PXR and induced PXR target gene expression in vitro and in vivo. Short-term exposure to amprenavirsignificantly increased plasma total cholesterol and atherogenic low-density lipoprotein cholesterol levels in wild-type mice, but not in PXR-deficient mice [3]. Amprenavir has been approved for adults and children; the recommended capsule doses are 1200 mg twice daily for adults and 20 mg/kg twice daily or 15 mg/kg 3 times daily for children < 13 years of age or adolescents < 50 kg [1].

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Peptidomimetic Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Cytokine Inhibitors Library  |  Chloroquine  |  Doxorubicin hydrochloride  |  Dexamethasone  |  5-Fluorouracil  |  Thapsigargin  |  ALC-0315  |  Q-VD-OPh  |  Nirmatrelvir  |  Valproic acid  |  Imatinib  |  Panobinostat  |  Shikonin  |  Aloxistatin  |  Molnupiravir  |  Hydroxyurea  |  Probenecid  |  Remdesivir  |  Kaempferol  |  Plerixafor  |  Dimethyl fumarate  |  Pepstatin  |  Birinapant  |  Imiquimod  |  Brequinar  |  Paquinimod  |  Maraviroc  |  Hydroxychloroquine sulfate  |  GSK3326595  |  Baicalin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds